Genetic variation that predicts platinum sensitivity reveals the role of miR-193b&z.ast; in chemotherapeutic susceptibility

Molecular Cancer Therapeutics

Volumn 11, Issue 9, 2012, Pages 2054-2061

  Ziliak, Dana ^a   Gamazon, Eric R ^a   LaCroix, Bonnie ^a   Im, Hae Kyung ^a   Wen, Yujia ^a   Huang, Rong Stephanie ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; MICRORNA; MICRORNA 193B; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CCR6 GENE; CRIM1 GENE; CYP2R1 GENE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAMD1B GENE; HAPLOTYPE MAP; IFIT2 GENE; KCNMA1 GENE; KSNMA1 GENE; KYNU GENE; OAS1 GENE; ONCOGENE; OVARY CANCER; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PSTPIP2 GENE; RAPGEF5 GENE; SHFM3P1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC2A5 GENE; USP12 GENE; ZHX12 GENE;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLOTYPES; HAPMAP PROJECT; HUMANS; INHIBITORY CONCENTRATION 50; MICRORNAS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84866077606     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0221     Document Type: Article

References (36)

1. Williams C, Whitehouse J. Cis-platinum: a new anticancer agent. Br Med J 1979;1:1689-91. (Pubitemid 9200322)
2. Huang RS, Duan S, Kistner EO, Christine HM, Dolan ME. Genetic variants assoicated with carboplatin-induced cytotoxicity in cell lines derived from Africans.Mol Cancer Ther 2008;7:3038-46.
3. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity using a genome-wide approach. AmJ HumGenet 2007;81:427-37. (Pubitemid 47330203)
4. Gamazon E, Huang R, Dolan M, Cox N. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol 2011;12:R46.
5. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011;17:5490-500.
6. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, et al. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 2011;157:265-72.
7. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci 2010;107:9287-92.
8. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk R, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005;120:21-4. (Pubitemid 40094599)
9. Lewis B, Burge C, Bartel D. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20. (Pubitemid 40094598)
10. Chitwood D, Timmermans M. Small RNAs are on the move. Nature 2010;467:415-9.
11. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anti-cancer therapy. Cancer Res 2007;67:11111-6. (Pubitemid 350248533)
12. International HapMap Consortium.The International HapMap Project. Nature 2003;426:789-96.
13. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-73.
14. Huang RS, Kistner EO, Bleibel WK, Shukla SJ, Dolan ME. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther 2007;6:31-6. (Pubitemid 46206666)
15. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, et al. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet 2008;82:631-40.
16. Gamazon ER, Ziliak D, ImHK, LaCroix B, Park D, Cox NJ, et al. Genetic architecture of microRNA expression: Implications for the transcriptome and complex traits. Am J Hum Genet 2012;90:1046-63.
17. Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, et al. Population differences in microRNA expression and biological implications. RNA Biol 2011;8:692-701.
18. Wheeler H, Gamazon E, Stark A, O'Donnell P, Gorsic L, Huang R, et al. Genome-wide meta-analysis identi fies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 2011 Aug 16;Epub ahead of print.
19. Gamazon E, Duan S, Zhang W, Huang R, Kistner E, Dolan M, et al. PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics 2010;20:269-73.
20. Gamazon ER, Im HK, Duan S, Lussier YA, Cox NJ, Dolan ME. ExprTarget: an integrative approach to predicting human microRNA targets. PLoS One 2010;5:e13534.
21. Storey JD, Tibshirani R. Statistical significance for genome-wide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
22. Huang D, Sherman B, Lempicki R. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
23. Huang D, Sherman B, Lempicki R. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13.
24. Shankavaram U, Varma S, Kane D, Sunshine M, Chary K, Reinhold W, et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 2009;10:277.
25. é GC, Zhang X, Pemberton JGW, Garady C, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010;176:2520-9.
26. Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009;28:3937-48.
27. Rauhala H, Jalava S, Isotalo J, Bracken H, Lehmusvaara S, Tammela T, et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010;127:1363-72.
28. Unno K, Zhou Y, Zimmerman T, Platanias L, Wickrema A. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma 2009;50:1865-71.
29. Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 2009;28:3926-36.
30. Hu Z, Shu Y, Chen Y, Chen J, Dong J, Liu Y, et al. Genetic polymorphisms in the precursor microRNA flanking region and non-small cell lung cancer survival. Am J Respir Crit Care Med 2011;183:641-8.
31. Wilkinson L, Kolle G, Wen D, Piper M, Scott J, Little M. CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. J Biol Chem 2003;278:34181-8. (Pubitemid 37553260)
32. Iwaniuk K, Schira J, Weinhold S, Jung M, Adjaye J, Müller H, et al. Network-like impact of microRNAs on neuronal lineage differentiation of unrestricted somatic stem cells from human cord blood. Stem Cells Dev 2011;20:1383-94.
33. He J, Zhang J, Yi C, Lv Q, Xie W, Li J, et al. miRNA-mediated functional changes through co-regulating function related genes. PLoS One 2010;5:e13558.
34. Prenkert M, Uggla B, Tidefelt U, Strid H. CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells. Anticancer Res 2010;30:4157-61.
35. Stawowczyk M, Van Scoy S, Kumar K, Reich N. The interferon stimulated gene 54 promotes apoptosis. J Biol Chem 2011;286: 7257-66.
36. Wen Y, Gorsic L, Wheeler H, Ziliak D, Huang R, Dolan M. Chemother-apeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics 2011;21:476-88.